Literature DB >> 22848268

CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer.

Hiromi Yasuda1, Koji Tanaka, Yoshiki Okita, Toshimitsu Araki, Susumu Saigusa, Yuji Toiyama, Takeshi Yokoe, Shigeyuki Yoshiyama, Aya Kawamoto, Yasuhiro Inoue, Chikao Miki, Masato Kusunoki.   

Abstract

Stem cells are thought to contribute to tissue regeneration as well as carcinogenesis. Ulcerative colitis-associated colorectal cancer (UC-CRC) has shown distinct characteristics compared with those of sporadic CRC. The aim of this study was to evaluate the expression of stem cell markers CD133, OCT4 and NANOG in UC-CRC and the inflamed colonic epithelium of UC patients. Total RNAs of UC-CRC (n=6), inflamed colonic epithelium (n=24), sporadic CRC (n=37) and adjacent normal colonic epithelium (n=37) were isolated from formalin-fixed, paraffin-embedded specimens using microdissection techniques in order to purify colonic epithelial cells. Relative mRNA levels of CD133 (PROM), OCT4 (POU5F1) and NANOG were measured using real-time reverse transcription polymerase chain reaction. Three stem cell markers were also investigated immunohistochemically. PROM, POU5F1 and NANOG levels were found to be significantly lower in UC-CRC than in inflamed colonic epithelium of UC patients. By contrast, sporadic CRC showed a significantly higher expression of PROM, POU5F1 and NANOG compared with adjacent normal colonic epithelium. POU5F1 and NANOG levels were significantly lower in UC-CRC than in sporadic CRC. PROM and NANOG levels in inflamed colonic epithelium were significantly higher among younger UC patients (P<0.05). Longer disease duration was significantly associated with lower PROM expression (P=0.0117). No significant difference was found in PROM levels between UC-CRC and inflamed colonic epithelium in patients with longer disease duration. UC-CRC showed different expression profiles of stem cell markers compared with sporadic CRC. Decreases in PROM expression of inflamed colonic epithelium may identify UC patients at high risk for the development of UC-CRC.

Entities:  

Year:  2011        PMID: 22848268      PMCID: PMC3406567          DOI: 10.3892/ol.2011.415

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

2.  Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma.

Authors:  K E Bijwaard; N S Aguilera; Y Monczak; M Trudel; J K Taubenberger; J H Lichy
Journal:  Clin Chem       Date:  2001-02       Impact factor: 8.327

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

5.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

6.  Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells.

Authors:  Jiancong Liang; Ma Wan; Yi Zhang; Peili Gu; Huawei Xin; Sung Yun Jung; Jun Qin; Jiemin Wong; Austin J Cooney; Dan Liu; Zhou Songyang
Journal:  Nat Cell Biol       Date:  2008-05-04       Impact factor: 28.824

7.  Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis.

Authors:  M D Rutter; B P Saunders; G Schofield; A Forbes; A B Price; I C Talbot
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

8.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

Review 9.  The cancer stem cell hypothesis: in search of definitions, markers, and relevance.

Authors:  Michail Shipitsin; Kornelia Polyak
Journal:  Lab Invest       Date:  2008-03-31       Impact factor: 5.662

10.  Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis.

Authors:  Takayuki Matsumoto; Shotaro Nakamura; Yukihiko Jo; Takashi Yao; Mitsuo Iida
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

View more
  13 in total

1.  Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug.

Authors:  Chun Sun; Lu Sun; Yan Li; Xiaonan Kang; Shu Zhang; Yinkun Liu
Journal:  Med Oncol       Date:  2013-02-21       Impact factor: 3.064

2.  Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients.

Authors:  Raheleh Roudi; Mahboubeh Barodabi; Zahra Madjd; Giandomenico Roviello; Silvia Paola Corona; Mahshid Panahei
Journal:  Mol Cell Oncol       Date:  2020-07-14

Review 3.  Inflammatory bowel disease and carcinogenesis.

Authors:  Hiroko Nagao-Kitamoto; Sho Kitamoto; Nobuhiko Kamada
Journal:  Cancer Metastasis Rev       Date:  2022-04-13       Impact factor: 9.237

4.  Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer.

Authors:  Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal
Journal:  Mol Med       Date:  2016-09-12       Impact factor: 6.354

5.  Association of hepatocyte-derived growth factor receptor/caudal type homeobox 2 co-expression with mucosal regeneration in active ulcerative colitis.

Authors:  Ferenc Sipos; Miklós Constantinovits; Gábor Valcz; Zsolt Tulassay; Györgyi Műzes
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 6.  ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer.

Authors:  Stefanie Hahn; Heiko Hermeking
Journal:  J Mol Med (Berl)       Date:  2014-05-18       Impact factor: 4.599

7.  Oct-4 is associated with gastric cancer progression and prognosis.

Authors:  Wen-Li Jiang; Peng-Fei Zhang; Guo-Feng Li; Jian-Hua Dong; Xue-Song Wang; Yuan-Yu Wang
Journal:  Onco Targets Ther       Date:  2016-01-27       Impact factor: 4.147

8.  Altered Expression of High Molecular Weight Heat Shock Proteins after OCT4B1 Suppression in Human Tumor Cell Lines.

Authors:  Mohammad Reza Mirzaei; Mohammad Kazemi Arababadi; Malek Hossein Asadi; Seyed Javad Mowla
Journal:  Cell J       Date:  2016-01-17       Impact factor: 2.479

9.  Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway.

Authors:  Hai Lin; Li-Hua Sun; Wei Han; Tie-Ying He; Xin-Jian Xu; Kun Cheng; Cheng Geng; Li-Dan Su; Hao Wen; Xi-Yan Wang; Qi-Long Chen
Journal:  Mol Med Rep       Date:  2014-07-07       Impact factor: 2.952

10.  Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression.

Authors:  Wojciech Jóźwicki; Anna A Brożyna; Jerzy Siekiera
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.